Source: International Congress 2014 – Tuberculosis: epidemiology and public health
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
M. Kikvidze, L. Ikiashvili (Tbilisi, Georgia). Comorbidities and MDR-TB treatment outcomes in Georgia- 2009-11 cohort. Eur Respir J 2014; 44: Suppl. 58, 1444

Member's Comments

No comment yet.

Related content which might interest you: Impact of diabetes mellitus on drug-resistant tuberculosis treatment outcomes in Georgia – Cohort study Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 MDR-TB treatment outcomes in HIV positive patients Source: International Congress 2014 – Tuberculosis: from diagnosis to therapy and prevention Year: 2014 Co-morbid conditions associated with tuberculosis (TB): Results from a 1-day, point-prevalence study in 204,912 physician diagnosed patients from 880 cities and towns in India Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management II Year: 2013 Failure predictors when treating MDR-TB Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) cases at a referral hospital of infectious diseases in Italy Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Treatment outcomes and deaths among multidrug-resistant tuberculosis (MDR-TB) patients in Gomel region, Belarus – 2009-2010 Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013 Could side effects of MDR-TB treatment change the outcome of the disease? Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Indicators of rifampicin-resistant TB response in Belarus, 2009-2014 Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 The death analysis of HIV-infected patients in the antituberculous hospital Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 1 Year: 2014 Efficacy of treatment of MDR/XDR TB patients with diabetes mellitus Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Impact of social support programme on MDR-TB patients' treatment outcomes Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3 Year: 2014 Risk factors for tuberculosis relapse in Polish patients Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Treatment outcome among HIV positive and HIV negative TB patients in Chandigarh, India: A retrospective cohort study Source: International Congress 2015 – Management of TB: a patient focus Year: 2015 Healing predictors when treating MDR-TB Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Predictors of defaulting from treatment among patients with tuberculosis Source: International Congress 2015 – Management of TB: a patient focus Year: 2015 Clinical profile of MDR-TB patients and their early response to DOTS PLUS: An Indian perspective Source: Annual Congress 2013 –Tuberculosis: clinical aspects Year: 2013 Addressing the tuberculosis (TB) and diabetes mellitus (DM) co-epidemic among TB patients in Luanda, Angola Source: International Congress 2016 – Epidemiological aspects of tuberculosis and other respiratory conditions: from lung cancer to late-onset Pompe's disease Year: 2016 Time to sputum culture conversion as a prognostic marker for end-of-treatment outcome in the first cohorts of MDR-TB patients managed in a Nigerian tertiary hospital Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Treatment outcomes of MDR-TB patients notified in Romania during 2005-2007 Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Latent tuberculosis infection prevalence and risk of developing active TB among patients eligible for starting anti-TNFα therapy Source: International Congress 2015 – Screening strategies in TB Year: 2015